Sight Sciences (SGHT) director and 10% owner buys 13,958 shares

Rhea-AI Filing Summary

Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 13,958 shares of common stock on 12/16/2025 at a weighted average price of $8.308 per share. The shares were bought in multiple trades at prices ranging from $8.12 to $8.40.

After this transaction, Encrantz directly beneficially owns 1,391,922 shares, which include 30,952 restricted stock units subject to vesting. He is also reported as having indirect beneficial ownership of 632,456 shares held by a revocable trust where he serves as trustee, and 5,086,920 shares held by Allegro Investment Fund, L.P., although he disclaims pecuniary interest and beneficial ownership in the Allegro-held shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Encrantz Staffan

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		P		13,958	A	$8.308(1)	1,391,922(2)	D
Common Stock								632,456	I	See footnote(3)
Common Stock								5,086,920	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $8.12 to $8.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. Includes (i)1,360,970 shares of Common Stock and (ii) 30,952 restricted stock units which are subject to vesting as previously reported.

3. These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any.

4. These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the Chairman and CEO and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose.

	/s/Jeremy Hayden, Attorney-in-Fact for Staffan Encrantz	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sight Sciences (SGHT) report for Staffan Encrantz?

Staffan Encrantz reported an open-market purchase of 13,958 shares of Sight Sciences common stock on 12/16/2025 at a weighted average price of $8.308 per share.

At what prices did Staffan Encrantz buy Sight Sciences (SGHT) shares?

The 13,958 shares were purchased in multiple trades at per-share prices ranging from $8.12 to $8.40, resulting in a weighted average price of $8.308.

How many Sight Sciences (SGHT) shares does Staffan Encrantz directly own after this transaction?

Following the reported purchase, Staffan Encrantz directly beneficially owns 1,391,922 shares of Sight Sciences common stock, including 30,952 restricted stock units subject to vesting.

What indirect holdings of Sight Sciences (SGHT) shares are associated with Staffan Encrantz?

The filing reports 632,456 shares held by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust and 5,086,920 shares held by Allegro Investment Fund, L.P., with which Encrantz is affiliated.

Does Staffan Encrantz claim beneficial ownership of all indirectly held Sight Sciences (SGHT) shares?

The filing states that Encrantz may be deemed to beneficially own shares held by the revocable trust but disclaims beneficial ownership except to any pecuniary interest. For shares held by Allegro Investment Fund, L.P., he reports them voluntarily and disclaims beneficial ownership and pecuniary interest.

What is Staffan Encrantz’s relationship to Sight Sciences (SGHT)?

Staffan Encrantz is reported as a Director of Sight Sciences and a 10% owner of the company’s common stock.